Working group on food contact materials under PAFF section novel food and toxicological safety of the food chain (SANTE/E-2), 27 April 2023

Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs and protocol for the risk assessment strategy





EC REGULATORY UPDATE OF BPA IN FEB 2018

Following the 2015 BPA EFSA opinion :

→ EC <u>amended</u> the Plastics **Regulation (EU) No 10/2011** with <u>lower</u> limits for BPA in plastics

 \rightarrow EC <u>introduced</u> new **Regulation (EU) 2018/213** applying the SML also to varnishes and coatings.

Plastic FCM: Reduction of the Specific Migration Limit (SML) for BPA from 0.6 mg/kg to 0.05 mg/kg of food

Plastic FCM: Extension of the ban on the use of BPA in the manufacture of polycarbonate baby bottles to sippy cups

Varnishes and coatings (e.g. interior of food cans): exceptional application of the same SML (0.05 mg/kg) as in plastics

Varnishes and coatings in articles specifically intended to come into contact with <u>young</u> <u>children's food</u>: SML of non-detect = NO migration (detection limit = 0.01 mg/kg) of BPA



Overview of previous EFSA evaluations on BPA

2015

Scientific opinion on BPA risk assessment (temporary-TDI: from 50 to 4 µg/kg bw per day)

2016

Statement on BPA immunotoxicity

2016

New two step-mandate on BPA hazard reevaluation by EC to EFSA



Annex Dear Dr Url, Subject: Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs and protocol for the risk assessment strateor.	MANDATE ON BPA'S RE-EVALUATION	EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Director -General 12 OTT. Brussels,
suategy		Dear Dr Url, Subject: Re-evaluation of the risks to public health related to the presence of

In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002², the European Commission asks EFSA to:

Step 1

Step 2

- establish a protocol detailing the criteria for new study inclusion and for toxicological evidence appraisal for the re-evaluation of BPA, to ensure an efficient and transparent re-assessment of BPA;
- re-evaluate the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. In particular, the re-evaluation should take into consideration new data available from the results of the US NTP/ FDA study due in 2017 as well as all other new available information not previously evaluated by EFSA and which fulfil the criteria laid down in an established protocol. This re-evaluation should seek to clarify the remaining uncertainties concerning the toxicological endpoints of BPA, especially those concerning the mammary gland, reproductive, metabolic, neurobehavioural and immune systems and to establish a full tolerable daily intake (TDI) on the basis of the new information available.



EC MANDATE (2016): TWO-STEP APPROACH

1st step: BPA hazard assessment protocol

2nd step: Re-evaluation of BPA safety

etsa TECHNICAL REPORT ersa TECHNICAL REPORT APPROVED: 30 November 2017 doi:10.2903/sp.efsa.2017.EN-1 APPROVED: 24 October 2019 doi:10.2903/sp.efsa.2019.EN-1732 Bisphe Testing the study appraisal methodology from the 2017 Bisphenol A (BPA) hazard assessment protocol Ursula Gundert-Rem European Food Safety Authority (EFSA) Hass, Carlijn Hooijma Wölfle, Fulvi Cristina Croera, Monika Batke, Emanuela Corsini, Rex E. FitzGerald, David Gott, Evangelia Ntzani, Ursula Gundert-Remy, Thorhallur Halldorsson, Henri Schroeder, Eugenio Scanziani, Inger-Lise Steffensen, Beate Ulbrich, Ine Waalkens-Berendsen, Detlef Wölfle, Fulvio Barizzone, Federica Barrucci, Ellen Van Haver, Anna F. Castoldi and Henk Van Loveren Revisions of the methodology were applied

before the full implementation


• Seek to clarify the remaining uncertainties

 Take into consideration new data from the US NTP/FDA study, as well as all other new available information



(draft opinion endorsed on 24 Nov 2021; final opinion adopted on 6 Dec. 2022 and published on 19 Apr. 2023)

PROTOCOL: SYSTEMATIC APPROACH



PUBLIC CONSULTATION – DRAFT OPINION BPA

• 24 November 2021

The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) **endorsed for public consultation** the draft scientific opinion.

• 15 December 2021 to 22 February 2022 Public consultation open

Interested parties submitted comments using the dedicated EFSA webpage.

https://connect.efsa.europa.eu/RM/s/publicconsult ation2/a0l1v00000E8BRD/pc0109 Re-evaluation of Bisphenol A (BPA)

Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs

EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP),

Claude Lambré, José Manuel Barat Baviera, Claudia Bolognesi, Andrew Chesson, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Marcel Mengelers, Alicja Mortensen, Gilles Rivière, Vittorio Silano (until 21 December 2020†), Inger-Lise Steffensen, Christina Tlustos, Laurence Vernis, Holger Zorn, Monika Batke, Margherita Bignami, Emanuela Corsini, Rex FitzGerald, Ursula Gundert-Remy, Thorhallur Halldorsson, Andrew Hart, Evangelia Ntzani, Henri Schroeder, Eugenio Scanziani, Beate Ulbrich, Dina Waalkens-Berendsen, Detlef Woelfle, Zainab Al Harraq, Katleen Baert, Anna F. Castoldi, Maria Carfi, Cristina Croera and Henk Van Loveren

Abstract

In 2015, EFSA established a temporary tolerable daily intake (t-TDI) for BPA of 4 µg/kg bw per day. In 2016, the European Commission (EC) mandated EFSA to re-evaluate the risks to public health from the presence of BPA in foodstuffs and to establish a full tolerable daily intake (TDI). For this re-evaluation, a pre-established protocol which had undergone public consultation was used. The CEP Panel concluded that it is Unlikely to Very Unlikely that BPA presents a genotoxic hazard through a direct mechanism. Therefore, it was concluded that the balance of evidence allows a health-based guidance value (HBGV) to be established. The immune system was identified as the most sensitive health outcome category to BPA exposure. Specifically, an increase of Th17 cells was identified as the critical effect; these cells are pivotal in cellular immune mechanisms and involved in the development of allergic lung inflammation. A reference point (RP) of 0.93 ng/kg bw per day, expressed as human equivalent dose, was identified for the critical effect. The uncertainty analysis indicated that it was around 90% probable that no other endpoint was more sensitive than Th17 cells. Therefore, the CEP Panel concluded that no additional uncertainty factor (UF) was needed and that a HBGV based on the identified RP is justified. Applying an UF of 25 to the RP, a TDI of 0.04 ng BPA/kg bw per day was established. Comparison of this TDI with the dietary exposure estimates from the EFSA 2015 opinion showed that both the mean and the 95th percentile dietary exposures in all age groups exceeded the TDI by two to four orders of magnitude. Even considering the uncertainty in the exposure assessment, since the exceedance was so large, the CEP Panel concluded that there is a health concern from dietary BPA exposure for all age groups.

© European Food Safety Authority, 2021. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

ENGAGEMENT ACTIVITIES

- Stakeholders and interested parties: public meeting on 24 Jan.
 2022
- EU Member states: 25 Jan. 2022
- US FDA: 7 Feb. 2022
- European Medicines Agency: 16 Feb, 29 Nov 2022
- EFSA Scientific Committee: 22 and 28 April 2022


Thematic workshop on biomarkers of effects: 22-23 Sept. 2022

Comments received from the Public Consultation


- Comments submitted by 62 interested parties from 21 countries
 Individual companies, industry organisations, scientific associations, public agencies, university, NGOs, consultancy firms, individuals in their personal capacity and anonymous contributors
 - 46 interested parties submitting on behalf of affiliation/organisation
 - 16 interested parties submitting on personal capacity
- 301 comments received in total, out of which:
 - 181 unique comments containing one or more issues
 ⇒ responded on a one-by-one basis
 - 96 duplicate comments
 - 19 empty comments
 - 5 comments outside the remit of the opinion



SECTION DISTRIBUTION OF PUBLIC COMMENTS (N=181)



OVERVIEW OF <u>MAIN POINTS ADDRESSED</u> IN RESPONSE TO PC



BPA re-evaluation: problem formulation

• **Aim** of this hazard assessment:

To assess whether the new scientific evidence still supports the previous t-TDI for BPA of 4 μ g/kg bw per day.


- Decision should be based on the evaluation of:
 - (i) **adverse effects in humans** associated with the exposure to BPA via any route;
 - (ii) **adverse effects in animals** after exposure to BPA via any route;
 - (iii) human and animal **toxicokinetics** of BPA



Health Outcome Categories assessed

- Assessed endpoints were grouped into structural and/or functional clusters for eight health outcome categories (HOCs):
 - General toxicity
 - Immunotoxicity
 - Metabolic effects
 - Neurotoxicity and developmental neurotoxicity
 - Reproductive and developmental toxicity
 - Cardiotoxicity
 - Carcinogenicity and mammary gland proliferative effects
 - Genotoxicity





Hazard Identification



IMMUNOTOXICITY HAZARD IDENTIFICATION: INTEGRATED LIKELIHOOD

Human	stream	Animal stream Cluster Overall likelihood		Integrated likelihood	
Cluster	Overall likelihood				
Asthma/ allergy	ALAN (P, C)	Allergic lung inflammation Likely (D, A)		Likely	
		Cellular immunity Likely (D)		Likely	
		Inflammation	Likely (G)	Likely	
		Humoral immunity	ALAN (D)	ALAN	
		Innate immunity	ALAN (D)	ALAN	
P: Exposure during pregnancy C: Exposure during childhood		D: Developmental (pre- / post-natal until weaning) exposure G: Growth phase / young age exposure A: Adult exposure		15	

REPRODUCTIVE AND DEVELOPMENTAL TOXICITY HAZARD IDENTIFICATION: INTEGRATED LIKELIHOOD

Human strea	m	Animal	Animal stream		
Cluster	Overall likelihood	Cluster	Overall likelihood	Integrated likelihood	
		Developmental toxicity	ALAN (D, D&A,G)	ALAN	
Fetal and Post-natal Growth	Not Likely (P)			Not Likely	
Pubertal/Endocrine	ALAN (P)			ALAN	
Female fertility	ALAN (A)	Female reproductive toxicity	Likely (D,D&A,G,A)	Likely	
Male fertility	Not Likely (A)	Male reproductive toxicity	Likely (D&A,G,A)	Likely	
Prematurity	Not Likely (P)			Not Likely	
Pre-eclampsia	ALAN			ALAN	
P: Exposure during pregna C: Exposure during childho A: Adult exposure	-	D: Developmental (pre- / pos D&A: Developmental until ac G: Growth phase / young ag A: Adult exposure	•	re 16	

METABOLIC EFFECTS HAZARD IDENTIFICATION: INTEGRATED LIKELIHOOD (1/2)


Huma	an stream	Anima	Animal stream	
Cluster	Overall likelihood	Cluster	Overall likelihood	Integrated likelihood
Obesity	ALAN (A)	Obesity	ALAN (D, D&A, G)	ALAN
Thyroid effects	Not Likely (P)	Thyroid hormones	Not Likely (D, D&A, A)	Not Likely
Cardiometabolic effects	Not Likely (P)			Not Likely
T2DM	ALAN (A)			ALAN
Gestational Diabetes Mellitus	Not Likely (A)			Not Likely
P: Exposure during C: Exposure during A: Adult exposure		D&A: Developmental until ad G: Growth phase / young age A: Adult exposure	D: Developmental (pre-/post-natal until weaning) exposure D&A: Developmental until adulthood exposure G: Growth phase / young age exposure A: Adult exposure I: Indirect (germline) exposure	

METABOLIC EFFECTS HAZARD IDENTIFICATION: INTEGRATED LIKELIHOOD (2/2)

Human stream		Animal stream			
Cluster	Overall likelihood	Cluster	Overall likelihood	Integrated likelihood	
		Uric Acid	Likely (A)	Likely	
		T1DM	ALAN (G, A)	ALAN	
		Fat deposition in the liver	ALAN (D, G, A)	ALAN	
		Glucose regulation	ALAN (D, A, I)	ALAN	
		Blood lipids	ALAN (A)	ALAN	
		Other metabolic hormones	Not Likely (D, D&A, G, A)	Not Likely	
	ring pregnancy; Iring childhood; Ire	D: Developmental (pre-/post-natal until wea D&A: Developmental until adulthood exposu G: Growth phase / young age exposure A: Adult exposure I: Indirect (germline) exposure		18	

NEUROTOXICITY AND DEVELOPMENTAL NEUROTOXICITY HAZARD IDENTIFICATION: INTEGRATED LIKELIHOOD


	Human st	ream	Animal stream		Integrated	
Cl	luster	Overall likelihood	Cluster	Overall likelihood	likelihood	
(b de	eurodevelopment ehaviour after evelopmental kposure)	Not likely (P)	Behaviour	Likely (D, G, A, I)	Likely	
			Neuromorphology	Likely (D, G)	Likely	
			Nervous system functionality	Likely (A)	Likely	
P: Exposure during pregnancy C: Exposure during childhood		D: Developmental (pre- / post-natal until weaning) exposure G: Growth phase / young age exposure A: Adult exposure I: Indirect (germline) exposure		19		



Hazard characterisation



SELECTION OF THE EFFECTS FOR THE HAZARD CHARACTERISATION AND THE UNCERTAINTY ANALYSIS (UA)



Studies investigating Very likely or Likely effects, with at least 1 ctrl+ two BPA dose levels, were considered for benchmark dose (BMD) analysis.


All ALAN, Likely and Very likely clusters were included in the uncertainty analysis (UA).

TOXICOKINETICS: SELECTION OF THE HEDF

- □ The CEP Panel decided to use the median value of the AUCs from two human studies for the calculation of the Human Equivalent Dose Factor (HEDF).
- AUC data for mice were used from the 2015 EFSA opinion (EFSA CEF Panel, 2015)

Species (oral route)	AUC (nM × h)	HEDF (AUC animal/ AUC human)	
Human (Thayer et al., 2015 and Teeguarden et al., 2015) (median)	15.7		11
Mouse (Doerge et al., 2011)	0.244	0.0155	
			ak an

ENDPOINTS BROUGHT FORWARD FOR SELECTION REFERENCE POINT (RP)



BMD ANALYSES (BASED ON 2017 EFSA GUIDANCE)

- Of all endpoints considered for the identification of a RP, the effect of BPA on Th17 cells in mice was the most sensitive (i.e. lowest BMDL)
- Besides the immunotoxicity study, also studies in other health outcome categories, i.e. in reproductive toxicity (ratio of primordial and total follicles, sperm motility) and metabolism (uric acid), had BMDLs within a range of up to 7-fold higher compared to the BMDL for Th17 cells


Critical endpoint, Species	BMDL (HED)	Reference
Th17 cells, Mice	8.2 ng/kg bw per day	Luo et al., 2016
Hepatic uric acid, Mice	24.6 ng/kg bw per day	Ma et al., 2018
Primordial/Total follicles ratio, Mice	44 ng/kg bw per day	Hu et al., 2018
Sperm motility, Mice	53 ng/kg bw per day	Wang et al., 2016



UNCERTAINTY ANALYSIS

□ The uncertainty analysis was conducted in accordance with EFSA's guidance on uncertainty analysis, using a combination of methods appropriate to each step of the assessment (EFSA Scientific Committee, 2018).









Reference point (RP) for the critical effect: 8.2 ng/kg bw per day, expressed as human equivalent dose


Default UFs of 25

inter-species toxicodynamic difference (2.5)
intra-human variability in toxicokinetics and toxicodynamics (10)

Uncertainty analysis: additional UF of 2

Tolerable daily intake (TDI) = 0.2 ng BPA/kg bw per day





Risk characterisation



MAIN FINDINGS: RISK CHARACTERISATION

TDI: 0.2 ng BPA/kg bw per day



Dietary exposure estimates EFSA 2015 Opinion

Both the average and high **dietary exposures** in all age groups **exceeded the TDI** by two to three orders of magnitude

 Even considering the uncertainty in the exposure assessment, since the exceedance was so large, the CEP Panel concluded that there is a health concern from dietary BPA exposure for all age groups of the general population.







STAY CONNECTED

SUBSCRIBE TO

3

0

efsa.europa.eu/en/news/newsletters efsa.europa.eu/en/rss Careers.efsa.europa.eu – job alerts

LISTEN TO OUR PODCAST Science on the Menu –Spotify, Apple Podcast and YouTube

FOLLOW US ON TWITTER @efsa_eu (@plants_efsa (

@methods_efsa @animals_efsa FOLLOW US ON LINKEDIN Linkedin.com/company/efsa

in

 \bowtie

FOLLOW US ON INSTAGRAM @one_healthenv_eu CONTACT US efsa.europe.eu/en/contact/askefsa

